Global Blood Therapeutics, Inc. Contracts & Agreements
66 Contracts & Agreements
- Business Finance (15 contracts)
- Business Operations (2)
- Human Resources (25)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (5)
- Uncategorized (16)
- First Supplemental Indenture, dated as of October 5, 2022, between Global Blood Therapeutics, Inc. and U.S. Bank Trust Company, National Association, as trustee (Filed With SEC on October 5, 2022)
- Amendment No. 1 to License Agreement by and between the Registrant and Sanofi, dated April 15, 2022 (Filed With SEC on August 8, 2022)
- Agreement and Plan of Merger, dated as of August 7, 2022, among Pfizer Inc., Ribeye Acquisition Corp. and Global Blood Therapeutics, Inc (Filed With SEC on August 8, 2022)
- Amended and Restated U.S. Cash Incentive Bonus Plan (Filed With SEC on February 23, 2022)
- Amended and Restated Severance and Change in Control Policy (Filed With SEC on February 23, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on February 23, 2022)
- Indenture, dated as of December 17, 2021, between Global Blood Therapeutics, Inc. and U.S. Bank National Association, as trustee (Filed With SEC on December 17, 2021)
- Form of Capped Call Transaction Confirmation (Filed With SEC on December 17, 2021)
- Employment Offer Letter Agreement by and between the Registrant and Carrie Krehlik, dated June 15, 2021 (Filed With SEC on November 4, 2021)
- Employment Offer Letter Agreement by and between the Registrant and Kim Smith-Whitley, M.D., dated November 24, 2020 (Filed With SEC on August 3, 2021)
- License Agreement by and between the Company and Sanofi, dated March 12, 2021 (Filed With SEC on May 5, 2021)
- Amended and Restated 2015 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on February 24, 2021)
- Amended and Restated Cash Incentive Bonus Plan (Filed With SEC on February 24, 2021)
- Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder (Filed With SEC on February 24, 2021)
- Amended and Restated Severance and Change in Control Policy (Filed With SEC on February 24, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2021)
- Amended and Restated 2017 Inducement Equity Plan and forms of award agreements thereunder (Filed With SEC on August 5, 2020)
- Amended and Restated Severance and Change in Control Policy (amended and restated through May 26, 2020) (Filed With SEC on August 5, 2020)
- Amended and Restated 2015 Employee Stock Purchase Plan (Filed With SEC on May 6, 2020)
- Non-Employee Director Compensation Policy, as amended and restated on March 24, 2020 (Filed With SEC on May 6, 2020)
- Description of Securities (Filed With SEC on February 26, 2020)
- License and Collaboration Agreement by and between the Registrant and Syros Pharmaceuticals, Inc., dated December 17, 2019 (Filed With SEC on February 26, 2020)
- Loan Agreement by and among the Registrant, BioPharma Credit PLC, and Biopharma Credit Investments V (Master) LP, dated December 17, 2019 (Filed With SEC on February 26, 2020)
- Amended and Restated Severance and Change in Control Policy (Filed With SEC on January 9, 2020)
- Cash Incentive Bonus Plan (Filed With SEC on January 9, 2020)
- Change in Control Policy (Filed With SEC on November 7, 2019)
- Employment Offer Letter by and between the Registrant and Eric Fink, dated June 17, 2019 (Filed With SEC on August 7, 2019)
- Underwriting Agreement dated June 26, 2019 by and between Global Blood Therapeutics, Inc. and Cantor Fitzgerald & Co (Filed With SEC on June 28, 2019)
- Employment Offer Letter by and between the Registrant and Jung Choi, dated March 16, 2015 (Filed With SEC on May 10, 2019)
- Non-Employee Director Compensation Policy (Filed With SEC on February 27, 2019)
- Employment Offer Letter by and between the Registrant and Brian Cathers, Ph.D., dated January 21, 2019 (Filed With SEC on February 27, 2019)
- Underwriting Agreement dated December 7, 2018 by and between Global Blood Therapeutics, Inc. and Cantor Fitzgerald & Co., as representative of the several underwriters (Filed With SEC on December 12, 2018)
- Amendment between the Company and HCP, dated August 29, 2018 (Filed With SEC on August 30, 2018)
- Change in Control Policy (Filed With SEC on May 7, 2018)
- Employment Offer Letter Agreement by and between Registrant and Peter Radovich, dated October 15, 2014 (Filed With SEC on May 7, 2018)
- Employment Offer Letter Agreement by and between Registrant and Jung Choi, dated March 16, 2015 (Filed With SEC on May 7, 2018)
- Employment Offer Letter Agreement by and between Registrant and David Johnson, dated February 21, 2018 (Filed With SEC on May 7, 2018)
- Underwriting Agreement dated March 8, 2018 by and between Global Blood Therapeutics, Inc. and Wells Fargo Securities, LLC, as representative of the several underwriters (Filed With SEC on March 12, 2018)
- Underwriting Agreement dated December 15, 2017 by and between Global Blood Therapeutics, Inc. and Cantor Fitzgerald & Co., as representative of the several underwriters (Filed With SEC on December 19, 2017)
- Global Blood Therapeutics, Inc. (the Company) Change in Control Policy Adopted on July 23, 2015 (amended on January 6, 2016, July 5, 2017 and July 26, 2017) (Filed With SEC on August 1, 2017)
- THE COVE AT OYSTER POINT LEASE (Filed With SEC on March 22, 2017)
- 400 East Jamie Court Suite 101 South San Francisco, CA94080 ###-###-#### f ###-###-#### www.globalbloodtx.com (Filed With SEC on March 13, 2017)
- GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO, CA 94080 (Filed With SEC on March 13, 2017)
- 5,102,041 Shares GLOBAL BLOOD THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on February 22, 2017)
- SUBLEASE (Filed With SEC on November 9, 2016)
- Pricing Term Sheet [None.] (Filed With SEC on June 20, 2016)
- GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO, CA 94080 (Filed With SEC on April 4, 2016)
- GLOBAL BLOOD THERAPEUTICS, INC. FIRST AMENDMENT TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on March 29, 2016)
- GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO, CA 94080 (Filed With SEC on March 29, 2016)
- Exhibit 10.6 (Filed With SEC on March 29, 2016)
- GLOBAL BLOOD THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN (Filed With SEC on January 12, 2016)
- [] Shares Global Blood Therapeutics, Inc. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT [], 2015 (Filed With SEC on July 31, 2015)
- Additional abbreviations may also be used though not in the above list. (Filed With SEC on July 31, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. 2015 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on July 31, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. DIRECTOR INDEMNIFICATION AGREEMENT (Filed With SEC on July 31, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on July 31, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on July 8, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. 2012 STOCK OPTION AND GRANT PLAN (Filed With SEC on July 8, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 575 SOUTH SAN FRANCISCO, CA 94080 (Filed With SEC on July 8, 2015)
- GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 575 SOUTH SAN FRANCISCO, CA 94080 (Filed With SEC on July 8, 2015)
- LEASE AGREEMENT (Filed With SEC on July 8, 2015)
- ASSIGNMENT AND ASSUMPTION OF LEASE (400 East Jamie Court) (Filed With SEC on July 8, 2015)
- LEASE AGREEMENT (Filed With SEC on July 8, 2015)
- 400 East Jamie Court Suite101 South San Francisco, CA 94080 t (650) 741-770 f ###-###-#### www.globalbloodtx.com (Filed With SEC on July 8, 2015)
- 400 East Jamie Court Suite101 South San Francisco, CA 94080 t (650) 741-770 f ###-###-#### www.globalbloodtx.com (Filed With SEC on July 8, 2015)
- 400 East Jamie Court Suite101 South San Francisco, CA 94080 t (650) 741-770 f ###-###-#### www.globalbloodtx.com (Filed With SEC on July 8, 2015)